AIM ImmunoTech Inc. secured acceptance of a late‑breaking abstract for its Phase 2 cisplatin‑resistant advanced recurrent ovarian cancer study at the 40th Annual Society for Immunotherapy of Cancer (SITC) meeting, scheduled for November 7, 2025.
The abstract, numbered 1343, will be presented in the Prince George ABC Exhibit Halls at the Gaylord National Resort and Convention Center. Acceptance of a late‑breaking abstract is reserved for studies that demonstrate significant clinical impact, underscoring the robustness and timeliness of the ovarian cancer data.
Ampligen (rintatolimod) is a first‑in‑class dsRNA TLR3 agonist. The Phase 2 data show an objective response rate of 45 %, a clinical benefit rate of 55 %, and a median progression‑free survival of 7.8 months—an improvement over pembrolizumab monotherapy. The acceptance signals that the data are compelling enough to warrant a high‑profile presentation and could accelerate regulatory discussions and partnership negotiations.
Despite the scientific milestone, AIM faces financial headwinds. Cash burn remains high and the current ratio is 0.1, indicating short‑term liquidity concerns. The stock is trading near its 52‑week low, and analyst consensus is mixed. CEO Thomas K. Equels emphasized the unmet need in advanced recurrent ovarian cancer and expressed confidence in Ampligen’s potential, while noting a new European patent for Long COVID that strengthens the company’s intellectual‑property portfolio.
No immediate market reaction has been reported; investors appear focused on liquidity concerns. The abstract acceptance may provide a tailwind for future funding, but short‑term valuation pressure persists.
AIM continues to pursue Ampligen across oncology and viral indications, but must balance clinical milestones with financial sustainability. The SITC presentation offers a platform to showcase data and attract potential partners, yet the company must address cash burn to maintain long‑term viability.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.